Skip to main content
. Author manuscript; available in PMC: 2019 Nov 27.
Published in final edited form as: J Am Coll Cardiol. 2018 Nov 27;72(21):2625–2641. doi: 10.1016/j.jacc.2018.09.042

Figure 6: Conceptual Illustration of Overlapping Phenotypes in CMD and Potential Therapeutic Strategies.

Figure 6:

(A) CMD phenotypes. (B) Potential therapeutic strategies. CMP = cardiomyopathy; CKD = chronic kidney disease; GLP-1 = glucagon-like peptide-1; HFpEF = heart failure with preserved ejection fraction; INOCA = ischemia and no obstructive CAD; IOCA = ischemia and obstructive CAD; PCSK-9 = pro-protein convertase subtilisin/kexin type 9; SGLT-2 = sodium-glucose cotransporter-2.